World News

Since the partnership began, Gilead has supplied more than 1.1 million vials of AmBisome and contributed over US$18 million in funding.

Idefirix is a first-in-class treatment designed to help highly sensitised adult kidney transplant patients who face difficulties finding compatible donors.

Yuhan operates two API manufacturing facilities in South Korea and has reported steady international growth, with overseas sales increasing 21% in the first quarter.

SmartIQ was developed in collaboration with leading cardiovascular centers to tackle one of the most persistent challenges in coronary imaging: balancing high-quality images with lower radiation exposure for both patients and healthcare professionals.

The acquisition reflects a long-term strategic collaboration between the two companies, with Artivion already serving as the exclusive distributor of NEXUS across Europe, the Middle East, and Africa since 2019.

Owen Mumford brings established expertise in device design, precision moulding, and medical device assembly, which will now be integrated with Embecta’s commercial infrastructure and large-scale manufacturing capabilities.

The solution integrates Syngo.CT Coronary Cockpit on the Syngo.via platform with Syngo PCI Connect running on Artis angiography systems.

The company’s presentations at EASL 2026 build on results from the Phase 3 ESSENCE programme, where semaglutide 2.4 mg previously demonstrated significant reductions in liver inflammation and fibrosis among patients with MASH.

Under the licensing arrangement, the Medicines Patent Pool (MPP) has invited qualified generic drug manufacturers to submit applications to produce generic versions of Xofluza.

Under the collaboration, the companies will evaluate Helicons both as standalone therapies and as payloads linked to Regeneron antibodies.